Tovorafenib

Phase 3

Day One Biopharmaceuticals, Inc. (DAWN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

DAWNPhase 2$2.2B

Tovorafenib Phase 2 Est. Readout

Tovorafenib• Low-grade Glioma141

Q2 2027~QConfirmed

CT.gov

00%

Mar '27

DAWNPhase 2$2.2B

Tovorafenib Phase 2 Est. Readout

Tovorafenib• Low-grade Glioma57

Mar 2027~Confirmed

CT.gov

00%

Competitive Landscape

2 competitors in Low-grade Glioma

View Full Landscape

Drug Information

Target Indication

Low-grade Glioma

Clinical Trial

NCT04775485

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/20/2026

Ojemda

Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2)

OrphanConditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

DAWN

Day One Biopharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Chemotherapeutic AgentPhase 3

Low-grade Glioma

Emi-LePhase 2

Triple Negative Breast Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts